投资咨询业务资格：证监许可【2011】1778 号 期货研究报告 有色金属 姓名：龙奥明 宝城期货投资咨询部 从业资格证号：F3035632 投资咨询证号：Z0014648 电话：0571-87006873 邮箱：longaoming@bcqhgs.com 作者声明 本人具有中国期货业协会授 予的期货从业资格证书，期货投 资咨询资格证书，本人承诺以勤 勉的职业态度，独立、客观地出 具本报告。本报告清晰准确地反 映了本人的研究观点。本人不会 因本报告中的具体推荐意见或观 点而直接或间接接收到任何形式 的报酬。 有色金属 | 日报 2026 年 2 月 4 日 有色日报 专业研究·创造价值 铜表现强势 核心观点 沪铜 今日沪铜主力期价整体围绕 10.5 万一线震荡运行，日内下探至 10.4 万下方，沪铜持仓量小幅上升。从盘面来看，前期悲观情绪得 到释放，市场氛围有所回暖，尾盘白银拉升带动有色盘面普涨。产 业层面，SMM 报道，隔月 Contango 月差小幅走扩，进一步促使持货 商将部分货源转为仓单，限制现货流动性进一步收紧。部分冶炼厂 选择备货交割，叠加持货商惜售挺价情绪明显，市场中可交易现货 有限，将支撑现货 ...

诚志股份公告，子公司青岛诚志华青超高分子量聚乙烯项目已完成全部设备安装调试以及试生产准备工 作，近日实现一次性投料试车成功，装置运行稳定并顺利产出粒度均匀、品质优良的产品。该项目采 用"釜式淤浆工艺"，在催化剂活性、聚合工艺与分子量分布控制等核心环节实现了系统性技术集成与创 新，有力保障了试车过程的高效平稳与产品品质的稳定可靠。项目的顺利试生产将优化公司产品结构， 延长烯烃产业链，提升市场竞争力，有望进一步增强公司盈利能力。 ...

Core Viewpoint - The article highlights the strategic importance of fine chemicals in China's economic transition towards high-quality development, with a focus on the IPO process of Hebei Caike New Materials Technology Co., Ltd. (Caike Technology) as a case study of how small and medium-sized enterprises can leverage capital markets for growth [2] Group 1: Company Overview - Caike Technology is recognized as a national-level high-tech enterprise and a "specialized, refined, and innovative" small giant, with significant achievements in research and development [3] - The company has a strong patent portfolio, holding 57 authorized patents, including 34 invention patents, showcasing its original innovation capabilities [3] Group 2: Technological Innovation - Caike Technology has developed key processes such as DMSS condensation acidification continuous chemical process and DATA green raw material oxidation process, which enhance product quality and reduce production costs and waste emissions [4] - The company has successfully extended its technological expertise into high-value emerging materials, achieving rapid sales growth from 5.37 million yuan in 2023 to 10.57 million yuan in the first half of 2025 [4] Group 3: Market Position and Performance - The company has established significant production capacity, with annual outputs of 15,000 tons of DMS, 4,500 tons of DMSS, 2,000 tons of DATA, and 5,000 tons of DMAS, positioning it favorably within the industry [6] - Caike Technology has formed long-term strategic partnerships with global leaders in the pigment and food colorant sectors, ensuring business stability and growth potential [6] Group 4: Financial Growth - In 2024, the company's main business revenue grew by 20.55%, with core products DATA and DMSS increasing by 20.66% and 55.94% respectively [7] - The growth momentum continued into the first half of 2025, with a 28.34% increase in main business revenue and significant year-on-year growth in key products [7] Group 5: IPO and Future Strategy - The decision to list on the Beijing Stock Exchange is a strategic move for Caike Technology, aligning with the evolving market ecosystem that now favors strong enterprises [8] - The IPO aims to raise funds for expanding production capacity, industrializing new materials, and upgrading the R&D center, reinforcing the company's leadership in high-performance pigment intermediates [8] Group 6: Industry Outlook - The transition of China's fine chemical industry towards high-end and green development is deemed essential, with Caike Technology exemplifying the value of a "specialized, refined, and innovative" small giant [9] - The ongoing IPO process is expected to further enhance the company's technological, scale, and brand advantages, contributing to China's journey from a petrochemical power to a petrochemical stronghold [9]

Financial Data and Key Metrics Changes - AMETEK reported record sales of $2 billion in Q4 2025, a 13% increase from Q4 2024, with organic sales up 5% and acquisitions contributing 7% [6][5] - Operating income reached a record $523 million, a 12% increase year-over-year, with operating margins at 26.2% and core margins at 27.6%, up 100 basis points [7][8] - EBITDA for the quarter was a record $618 million, up 10% from the previous year, with EBITDA margins at 30.9% [7] - Diluted earnings per share were a record $2.01, up 7% from Q4 2024, exceeding guidance [8] - Free cash flow was a record $527 million, up 6% year-over-year, with a conversion rate of 132% [8][24] Business Line Data and Key Metrics Changes - The Electronic Instruments Group (EIG) achieved sales of $1.37 billion, up 13% from the previous year, with organic sales up 2% and acquisitions contributing 10 points [9] - The Electromechanical Group (EMG) reported sales of $629 million, a 15% increase, with organic sales up 14% and operating income up 28% [10] - For the full year 2025, AMETEK established records for sales, operating income, and diluted earnings per share, with total sales of $7.4 billion, up 7% from 2024 [11] Market Data and Key Metrics Changes - Overall sales in the U.S. were up mid-single digits, while Europe saw low single-digit growth, and Asia experienced a 10% increase, driven by strong performance in China [41][43] - The process businesses grew mid-teens in Q4, with low single-digit organic growth, while Aerospace & Defense businesses saw low double-digit growth [40] Company Strategy and Development Direction - AMETEK announced the acquisition of LKC Technologies, enhancing its med tech exposure and broadening its ophthalmic portfolio [12][13] - The company plans to invest an incremental $100 million in growth initiatives in 2026, focusing on research, development, and technology innovation [15] - AMETEK aims to maintain a disciplined approach to capital deployment, prioritizing acquisitions while also considering share repurchases and dividends [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to offset inflation and tariffs through pricing strategies, expecting continued strong performance in 2026 [30][31] - The outlook for 2026 includes expected sales growth in the mid- to high-single digits, with diluted earnings per share projected to be between $7.87 and $8.07 [18] - Management noted a strong pipeline of acquisition candidates and a favorable M&A environment, indicating readiness to deploy significant capital [14][85] Other Important Information - AMETEK's effective tax rate for Q4 was 16.3%, with expectations for 2026 between 18.5% and 19.5% [22] - The company reported total debt of $2.3 billion at year-end, with cash and cash equivalents of $458 million [24] Q&A Session Summary Question: Can you provide insights into the medical portfolio performance? - Management indicated that the broader healthcare exposure accounts for 21% of the business, with Paragon and Rauland showing low double-digit growth in Q4 and high single digits for the full year [28] Question: What is the outlook for strategic pricing going forward? - Management stated that they expect to maintain a positive price-cost spread in 2026, successfully offsetting inflation and tariffs [30] Question: Can you discuss the performance of the process businesses? - Management noted that process businesses grew mid-teens in Q4, driven by recent acquisitions, with expectations for low single-digit organic growth in 2026 [40] Question: What is the status of the FARO acquisition? - Management expressed confidence in the integration of FARO, expecting to double EBITDA margins from mid-teens to 30% within three years [70] Question: How is the M&A pipeline looking for 2026? - Management reported a strong pipeline of acquisition opportunities, including larger deals, and emphasized their readiness to act on high-quality candidates [94][85]

Financial Data and Key Metrics Changes - AMETEK reported record sales of $2 billion in Q4 2025, a 13% increase from Q4 2024, with organic sales up 5% and acquisitions contributing 7% [4][5] - Operating income reached a record $523 million, up 12% year-over-year, with operating margins at 26.2% and core margins at 27.6%, an increase of 100 basis points [5][10] - Diluted earnings per share were a record $2.01, up 7% from the previous year, exceeding guidance [6][10] - Free cash flow was a record $527 million, up 6% year-over-year, with a conversion rate of 132% [6][22] Business Line Data and Key Metrics Changes - The Electronic Instruments Group (EIG) achieved sales of $1.37 billion, a 13% increase, with organic sales up 2% and acquisitions contributing 10 points [7] - The Electromechanical Group (EMG) reported sales of $629 million, up 15%, with organic sales up 14% and operating income increasing by 28% [9][10] Market Data and Key Metrics Changes - Overall orders increased by 18% to a record $2 billion, with organic orders up 7%, leading to a backlog of $3.58 billion [5][10] - U.S. and international sales were up mid-single digits, with Asia up 10%, driven by strong performance in China [41][42] Company Strategy and Development Direction - AMETEK announced the acquisition of LKC Technologies to enhance its med tech exposure, indicating a focus on strategic acquisitions to drive growth [4][12] - The company plans to invest an incremental $100 million in growth initiatives in 2026, building on a $90 million investment in 2025 [13] - AMETEK aims to maintain a disciplined approach to capital deployment, prioritizing acquisitions while also considering share repurchases and dividends [12][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate economic uncertainties and maintain strong performance, with expectations for mid- to high-single-digit sales growth in 2026 [17][18] - The company anticipates organic sales growth of low- to mid-single digits, with diluted earnings per share expected to rise 6%-9% [17][18] Other Important Information - AMETEK's effective tax rate for Q4 was 16.3%, with expectations for 2026 between 18.5% and 19.5% [20] - The company reported total debt of $2.3 billion, with cash and cash equivalents of $458 million, indicating a strong financial position [22][23] Q&A Session Summary Question: Can you provide insights into the medical portfolio performance? - Management noted that the broader healthcare exposure accounts for 21% of the business, with Paragon and Rauland showing low double-digit growth in Q4 and expected mid-single-digit growth in 2026 [25][26] Question: What is the outlook for strategic pricing going forward? - Management indicated a positive price-cost spread in Q4, with confidence in offsetting inflation and tariffs in 2026, supported by a differentiated product portfolio [27][28] Question: Can you discuss the performance of the process businesses? - The process businesses saw mid-teens growth in Q4, driven by recent acquisitions, with expectations for low single-digit organic growth in 2026 [35][36] Question: What is the status of the FARO acquisition? - Management expressed optimism about the FARO acquisition, highlighting synergies and the potential to improve EBITDA margins significantly over time [66][67] Question: How is the M&A pipeline looking for 2026? - Management reported a strong pipeline of high-quality acquisition candidates, with the capacity to deploy over $5 billion while maintaining an investment-grade credit rating [81][82]

"不同于普通钢板尺，它整合了日常检修的13种部件尺寸，让人工检修效率提升52%。"马耀锋介绍，多 年前他在检修中发现，普通钢板尺测量动车组部件微小缝隙时操作不便，便历时一个多月反复打磨、调 试，最终打造出这把实用的多功能尺。 (新春走基层)武汉"动车医生"：毫厘之间护航春运归途 中新网武汉2月3日电 (王梦媛 邹政 柯尊玮)2026年春运大幕已启，华中地区最大动车检修基地——武汉 动车段内每晚灯火通明。被称为"动车医生"的武汉动车运用车间地勤机械师马耀锋手持一把自制多功能 尺，精准塞入排障器与轨道的缝隙间。 如今，这一巧思已在全国多个动车运用所落地投用，成为春运检修一线的"效率神器"。而这一切，正源 于马耀锋始终秉持的工作理念："只有坚持问题导向，才能实现创新。" 编辑：董文博 随着中国铁路发展步伐加快，动车组车型持续更新、检修任务日益繁重，马耀锋深知，"一个人浑身是 铁，也打不了几根钉"。为进一步提升检修效率，2015年，以马耀锋名字命名的创新工作室成立，此 后，各类创新成果接连涌现。 怀揣着带动更多人投身技术创新的初心，以马耀锋创新工作室为核心、各车间孵化创新工作室为分支 的"1+N"工作模式应运而生。马 ...

近日，养元饮品旗下六个核桃正式官宣2026马年双代言人阵容，国民喜剧演员马丽与国际钢琴大师郎朗 联袂加盟，被网友称"六个核桃找到了马年'最对味'的代言人。" 这份坚持，首先源自对原料的严苛把控。资料显示，为保证高端品质，六个核桃在新疆、云南、太行山 三大核桃黄金产区建立专属原料基地，确保每一颗核桃都源自天然沃土。年均超过一亿公斤的核桃采购 量，不仅是规模的体现，更是对品质把控的彰显，为此，沙利文为六个核桃颁发了"核桃采购量全国第 一"权威证书。 除此之外，创新层面的技术积淀为六个核桃长青提供了硬核支撑。目前六个核桃拥有行业领先的技术 (5.3.28工艺、全核桃CET冷萃技术)，其通过靶向分离技术，精准去除核桃仁种皮中带来苦涩感的成 分，却完整保留了核桃营养，使得核桃蛋白、脂肪等营养成分的利用率大幅提升至97%以上，真正做到 了"去涩留香留营养"。 在此基础上，五重细化研磨工艺将核桃乳的颗粒细化至纳米级别，带来前所未有的细腻、顺滑口感，更 有利于人体消化吸收。从工艺体系的开创性研发，到持续依托国家级研发平台进行技术迭代，六个核桃 以科技守护天然、以创新提升价值的执着，实现了穿越周期，成为国民心中"品质年礼"代名 ...

央广网西安1月29日消息（记者侯凯奇）1月27日，陕西省第十四届人民代表大会第四次会议开幕。会议 期间，陕西省人大代表高禄梅提出：搭建AI+技术人才智力资源共享平台，助力企业技术创新，呼吁通过 搭建资源共享平台，通过机制化创新推动AI+技术在陕西更好发展。 陕西省人大代表高禄梅（央广网记者侯凯奇 摄） 高校作为科技创新的重要策源地，要加强基础研究和应用基础研究，强化科技成果转化，践行将科研成果 写在祖国大地上，破解卡脖子关键技术，将科研成果转化成经济生产力。 高 禄 梅 代 表 介 绍 ， 高 校 的 重 点 实 验 室 、 科 研 公 共 平 台 拥 有 先 进 的 仪 器 设 备 资 源 和 技 术 人 才 ， 自 2014 年 《 关 于 国 家 重 大 科 研 基 础 设 施 和 大 型 科 研 仪 器 向 社 会 开 放 的 意 见 》 （ 国 发 〔 2014 〕 70 号 ） 文 件 出 台 以 来，通过仪器设备设施的开放共享，充分整合大型仪器设备资源和技术人才资源，为高校教学科研和社会 科技创新企业提供了有效技术支撑。推动科技创新与产业创新深度融合，高校科研公共平台提质增效， 从"用起来"向" ...

Financial Performance - The company forecasts a net profit of between CNY 145 million and CNY 152 million for 2025, representing a year-on-year growth of 27.17% to 33.30% from CNY 114 million in the previous year [2][3] - The increase in performance is attributed to improved internal management, technological innovation, and market expansion [2][3] Product and Market Position - The production capacity ratio for black, white, colored masterbatches, and other products is approximately 6:2:1:1 [4] - The company holds over 30% market share in the domestic chemical fiber masterbatch industry, maintaining a strong competitive position through continuous innovation and market expansion [5] Research and Development - The company focuses on functional, green, and diversified product development, expanding into membrane and plastic applications while reinforcing its traditional strengths [6] - The company’s R&D efforts are aimed at enhancing product performance and expanding into new growth areas [6] Customer Base and Sales Structure - Approximately 60% of sales are to leading chemical fiber enterprises, while around 15% are to non-fiber applications such as automotive and film sectors [7] - The company’s core products are primarily used for coloring and functional modification of chemical fiber raw liquids, with a growing presence in non-fiber applications [7] International Expansion - The Turkish production base has been operating smoothly since its launch, focusing on local and overseas masterbatch markets, with plans for product line expansion and capacity enhancement in 2026 [8] - The company aims to leverage its Turkish base for further growth in the polyester and nylon masterbatch markets [8] Competitive Landscape - There is a trend of downstream chemical fiber companies establishing their own masterbatch production, but they lack the technical expertise and customization capabilities of specialized masterbatch suppliers [9] - The company plans to maintain its growth through technological upgrades and enhanced environmental performance [9] Strategic Projects - The Xiamen Luyi project, which optimizes and adds 20,000 tons of capacity, is running smoothly and is expected to enhance market share in South and East China [10][11] - The membrane and plastic division is focused on developing new functional films for diverse applications, achieving significant breakthroughs in key technical indicators [11] New Material Development - The subsidiary YaoKe New Materials is preparing for the production of 200 tons of COFs materials, with ongoing project approvals and facility preparations [11] - The project aims to achieve cost control through optimized processes and is focused on customer feedback for technical adjustments [11]

Core Viewpoint - The company and its subsidiaries have been granted a patent for an invention related to carbonyl reductase mutants and their applications, which is expected to enhance technological innovation and core competitiveness, although it will not have a significant impact on production and operations [1] Group 1 - The patent granted is for the invention titled "Carbonyl Reductase Mutant and Its Preparation Method, Application, and Preparation Method of ®-6-Hydroxy-8-Chlorooctanoic Acid Ethyl Ester" [1] - The patent number is ZL202211709938.1, with a validity period of 20 years [1] - The official announcement date of the patent is January 30, 2026 [1] Group 2 - The patent is expected to contribute to technological innovation within the company [1] - The patent will enhance the company's core competitiveness in the industry [1] - The company does not anticipate any major impact on its production and operations from this patent [1]